Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03777982 · ClinicalTrials.gov registry record · Phase 3
Conventional Androgen Deprivation Therapy (ADT) With or Without Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADT
A Phase 3 study, sponsored by Dana-Farber Cancer Institute.
- Terminated
- Registry status
- Phase 3
- Development phase
- 12
- Enrollment target
NCT03777982 is a Phase 3 study that was terminated before completion, run by Dana-Farber Cancer Institute. The registered enrollment target is 12 participants.
The verdict
NCT03777982, a Phase 3 study, was terminated before completion, sponsored by Dana-Farber Cancer Institute.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 12 participants
- Enrollment target
Study Summary
This research study is being offered to those patients who have received radiation therapy and who are receiving long-term hormonal therapy for their prostate cancer and whose PSA remains detectable despite having received at least 6, but no more than 12 months of hormonal therapy. The name of the study drugs involved in this study is: * LHRHA (luteinizing hormone-releasing hormone agonist or antagonist) * Abiraterone Acetate * Apalutamide * Prednisone
Interventions
- DRUG Apalutamide
- DRUG Prednisone
- DRUG Abiraterone Acetate
- DRUG LHRH Agonist or Antagonist
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2020-04-20 |
| Est. Completion | 2024-02-13 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03777982
The ClinicalTrials.gov registry entry for NCT03777982 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Apalutamide is the first listed.
NCT03777982 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03777982 about?
NCT03777982 is a clinical study titled "Conventional Androgen Deprivation Therapy (ADT) With or Without Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADT". This research study is being offered to those patients who have received radiation therapy and who are receiving long-term hormonal therapy for their prostate cancer and whose PSA remains detectable despite having received at least 6, but no more than 12 months of hormonal therapy. The name of the ...
What is the current status of trial NCT03777982?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 12 participants. The study started on 2020-04-20. Estimated completion is 2024-02-13.
What interventions are being tested in trial NCT03777982?
The interventions under investigation include: Apalutamide (DRUG), Prednisone (DRUG), Abiraterone Acetate (DRUG), LHRH Agonist or Antagonist (DRUG).
Who is sponsoring clinical trial NCT03777982?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.